Raltitrexed (Tomudex): an alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity
1998

Raltitrexed as an Alternative for Colorectal Cancer Patients with 5-FU Cardiotoxicity

Sample size: 2 publication Evidence: low

Author Information

Author(s): C-H Kohne, P Thuss-Patience, M Friedrich, PT Daniel, A Kretzschmarl, T Benterl, B Bauer, R Dietz, B Dorken

Primary Institution: Robert-Rossle-Klinik and Franz Volhard Klinik, Medizinische Fakultat Charite der Humboldt-Universitat zu Berlin

Hypothesis

Can raltitrexed be safely administered to patients with 5-FU-associated cardiotoxicity?

Conclusion

Raltitrexed can be safely administered to patients with 5-FU-associated cardiotoxicity without evidence of cardiac side effects.

Supporting Evidence

  • Both patients experienced cardiotoxicity from 5-FU but tolerated raltitrexed without cardiac side effects.
  • Patient 1 had normal coronary arteries and experienced chest pain only after high-dose 5-FU.
  • Patient 2 had a history of coronary artery disease but remained stable after receiving raltitrexed.

Takeaway

This study shows that raltitrexed is a safe option for patients who have heart problems caused by another cancer drug called 5-FU.

Methodology

Two case studies of patients with 5-FU-induced cardiotoxicity treated with raltitrexed.

Limitations

The study is based on only two case reports, limiting generalizability.

Participant Demographics

One female patient aged 58 and one male patient aged 62, both with colorectal cancer and a history of cardiotoxicity.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication